View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Chapter 2.5 120 Greece - G Germanidis (Papageorgiou General Hospital, Thessaloniki); G Hatzis (Laikon General Hospital, Athens); G Kitis, P Xiarchos (George Papanikolaou Hospital, Thessaloniki); M Raptopoulou-Gigi, E Gigi, E Sinakos (Aristototle University of Thessaloniki, Thessaloniki); I Vafi adis-Zouboulis, P Nicolaou, G Paraskevi (University of Athens Medical School, Athens). Italy - P Grima (S. Caterina Novella Hospital, Galatina); G Montalto (Universita di Palermo, Palermo); M Russello (Azienda Ospedaliera Garibaldi – Nesima, Catania); G Scifo (Presidio Ospedaliero Muscatello, Augusta); A Spadaro (University Hospital Messina, Messina); S Tripi (Universita di Palermo, Palermo). The Netherlands - MFC Beersma, ML op den Brouw, SD Diepstraten, GJ van Doornum, C van der Ent, A Heijens, A Keizerwaard, M Ouwendijk, G Ramdjan, LA van Santen, SMJ Scherbeijn, M Schutten, W Tielemans, AM Woltman, PE Zondervan (<strong>Erasmus</strong> MC University Medical Center, <strong>Rotterdam</strong>). Poland - A Kalinowska, TW Lapinski (Medical University of Bialystok, Bialystok); W Halota (Hospital Bydgoszcz, Bydgoszcz); T Mach (Medical College, Jagiellonian University, Krakow); M Pazgan-Simon (Medical University Wroclaw, Wroclaw). Turkey - G Ersoz (Ege University Faculty of Medicine, Izmir); N Sasmaz (Turkiye Yuksek lhtisas Hospital, Ankara); B Pinarbasi (Istanbul University Medical School, Istanbul); N Örmeci, Z Balik (Ankara University School of Medicine, Ankara); H Senturk (Istanbul University Cerrahpasa Medical School, Istanbul).
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72: Dynamic prediction of response to P
Page 77 and 78: References Dynamic prediction of re
Page 81 and 82: Cha pter 2.4 Dynamic prediction of
Page 83 and 84: INTRODUCTION Dynamic prediction of
Page 85 and 86: For the indirect approach we rewrit
Page 87 and 88: logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90: Dynamic prediction of response usin
Page 101 and 102: Table 1. Results of different stopp
Page 105: Dynamic prediction of response usin
Page 108 and 109: Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111: Chapter 2.5 108 and placebo daily.
Page 112 and 113: Chapter 2.5 110 for patients with a
Page 114 and 115: Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117: Chapter 2.5 114 peginterferon and n
Page 118 and 119: Chapter 2.5 116 hepatocellular carc
Page 120 and 121: Chapter 2.5 118 13. Werle-Lapostoll
Page 125: Cha pter 3 Statistical models of lo
Page 128 and 129: Chapter 3.1 126 ABSTRACT Background
Page 130 and 131: Chapter 3.1 128 METHODS Study desig
Page 132 and 133: Chapter 3.1 130 the presence of a c
Page 134 and 135: Chapter 3.1 132 ure 2 30 >3 x ULN 2
Page 136 and 137: Chapter 3.1 134 DISCUSSION The aim
Page 138 and 139: Chapter 3.1 136 References 1. Poyna
Page 140: Chapter 3.1 138 U i = Time to failu
Page 144 and 145: Chapter 3.2 142 Abstract We have de
Page 146 and 147: Chapter 3.2 144 multiple markers wa
Page 148 and 149: Chapter 3.2 146 The correlation bet
Page 150 and 151: Chapter 3.2 148 for our MLMM is fac
Page 152 and 153: Chapter 3.2 150 X and Z matrices fr
Page 154 and 155: Chapter 3.2 152 For each g =0,...,G
Page 156 and 157: Chapter 3.2 154 Focus of marginal,
Page 158 and 159: Chapter 3.2 156 Figure 1. Dutch PBC
Page 160 and 161: Chapter 3.2 158 Table 2. Dutch PBC
Page 166 and 167: Chapter 3.2 164 effects correct the
Page 168 and 169: Chapter 3.2 166 References 1. Kuipe
Page 170 and 171: Chapter 3.2 168 32. Tsiatis AA, Dav
Page 172:
Chapter 3.2 170 Table 4. Structure
Page 177 and 178:
Cha pter 4.1 Viral dynamics during
Page 179 and 180:
INTRODUCTION Viral dynamics during
Page 181 and 182:
V(t) = V 0 { A exp (-λ 1 t ) + (1-
Page 183 and 184:
Table 2. Dynamic parameters during
Page 185 and 186:
Figure 1. Viral dynamics during and
Page 187 and 188:
Viral dynamics during and after ent
Page 189 and 190:
References Viral dynamics during an
Page 191:
Viral dynamics during and after ent
Page 194 and 195:
Chapter 4.2 192 ABSTRACT Tenofovir,
Page 196 and 197:
Chapter 4.2 194 PATIENTS AND METHOD
Page 198 and 199:
Chapter 4.2 196 2 Slow: decline bet
Page 200 and 201:
Chapter 4.2 198 Table 2. Parameter
Page 202 and 203:
Chapter 4.2 200 9.0 8.0 7.0 6.0 5.0
Page 204 and 205:
Chapter 4.2 202 release. Although w
Page 206 and 207:
Chapter 4.2 204 References 1. Perri
Page 208:
Chapter 4.2 206 29. Lewin SR, Ribei
Page 212 and 213:
Chapter 4.3 210 ABSTRACT Treatment
Page 214 and 215:
Chapter 4.3 212 HBV DNA quantifi ca
Page 216 and 217:
Chapter 4.3 214 The resulting model
Page 218 and 219:
Chapter 4.3 216 Figure 1. Median HB
Page 220 and 221:
Chapter 4.3 218 Table 2: Pharmacoki
Page 222 and 223:
Chapter 4.3 220 Figure 3. effects r
Page 224 and 225:
Chapter 4.3 222 13-14 This model ta
Page 226 and 227:
Chapter 4.3 224 References 1. Kane
Page 228 and 229:
Chapter 4.3 226 25. Wolters LM, Han
Page 231:
Cha pter 5 Summary and conclusion
Page 234 and 235:
Summary and conclusion 232 Therapy
Page 236 and 237:
Summary and conclusion 234 who deve
Page 238 and 239:
Summary and conclusion 236 fi t mod
Page 241:
Cha pter 6 Samenvatting en conclusi
Page 244 and 245:
Samenvatting en conclusie 242 posit
Page 246 and 247:
Samenvatting en conclusie 244 De ve
Page 248 and 249:
Samenvatting en conclusie 246 en na
Page 250:
Samenvatting en conclusie 248 In ee
Page 255 and 256:
DANKWOORD Dankwoord 253 Met oplucht
Page 257:
CUR RICULUM VITAE Curriculum Vitae
Page 260 and 261:
Bibliography 258 Mechanical factors
Page 262 and 263:
Bibliography 260 35. Wolters LM, Ha
Page 264 and 265:
Bibliography 262 Volume Measurement
Page 266 and 267:
Bibliography 264 Quantitative HBV D
Page 268 and 269:
Bibliography 266 to Peginterferon-a
Page 272:
ISBN: 978-90-8559-069-9
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?